drugset / Trial / NCT06599528

A Comparing Study Between SJ04 and Ovidrel® in Healthy Subjects

NCT06599528

Phase 1 Recruiting 48 enrolled Suzhou Centergene Pharmaceuticals Co.,Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

This is a single-centre, randomised, open-label, single-dose, two-cycle, double-crossover study to compare the pharmacokinetics of SJ04 and Ovidrel® in healthy female subjects. Received a single subcutaneous injection administration of SJ04 Injection or Ovidrel®, both administered at a dose of 250 μg, once per cycle, and cross-administered after a washout period.

Timeline

Start
2024-08-12
Primary completion
2026-06-30
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Ovidrel Protein / enzyme biologic 250 ug Subcutaneous
Subject SJ04 Protein / enzyme biologic 250 ug Subcutaneous

Indications